{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:20:13Z","timestamp":1790432413769,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejpb.2019.06.029","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T10:38:30Z","timestamp":1561804710000},"page":"240-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model"],"prefix":"10.1016","volume":"142","author":[{"given":"Flavio C.","family":"Lombardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Perissutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.06.029_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40249-017-0286-2","article-title":"Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?","volume":"6","author":"Bergquist","year":"2017","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ejpb.2019.06.029_b0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","article-title":"Human schistosomiasis","volume":"368","author":"Gryseels","year":"2006","journal-title":"The Lancet"},{"key":"10.1016\/j.ejpb.2019.06.029_b0015","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.ejpb.2019.06.029_b0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0035-9203(02)90405-0","article-title":"Resistance of Schistosoma mansoni to praziquantel: is there a problem?","volume":"96","author":"Doenhoff","year":"2002","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejpb.2019.06.029_b0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/14787210.4.2.199","article-title":"Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance","volume":"4","author":"Doenhoff","year":"2006","journal-title":"Expert Rev. Anti-infective Therapy"},{"key":"10.1016\/j.ejpb.2019.06.029_b0030","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/infdis\/jiu506","article-title":"Mass drug administration (MDA) for schistosomiasis","volume":"211","author":"Wang","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2019.06.029_b0035","unstructured":"WHO. 201Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016."},{"key":"10.1016\/j.ejpb.2019.06.029_b0040","doi-asserted-by":"crossref","first-page":"E688","DOI":"10.1016\/S2214-109X(17)30187-0","article-title":"Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial","volume":"5","author":"Coulibaly","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ejpb.2019.06.029_b0045","article-title":"A rapid appraisal of factors influencing praziquantel treatment compliance in two communities endemic for schistosomiasis in Cote d'Ivoire","volume":"3","author":"Coulibaly","year":"2018","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.ejpb.2019.06.029_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","article-title":"Schistosomiasis","volume":"4","author":"McManus","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejpb.2019.06.029_b0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1208\/s12248-016-9885-2","article-title":"Pediatric biopharmaceutical classification system: using age-appropriate initial gastric volume","volume":"18","author":"Shawahna","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.06.029_b0060","article-title":"Praziquantel: A review","volume":"05","author":"Alsaqabi","year":"2014","journal-title":"J. Veter. Sci. Technol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13071-017-2293-3","article-title":"In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium","volume":"10","author":"Kovac","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ejpb.2019.06.029_b0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.06.029_b0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2006.03.028","article-title":"Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel","volume":"318","author":"Passerini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.06.029_b0080","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00436-002-0751-z","article-title":"Praziquantel","volume":"90","author":"Cioli","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejpb.2019.06.029_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2018.01.018","article-title":"A new soluble and bioactive polymorph of praziquantel","volume":"127","author":"Zanolla","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.06.029_b0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The cambridge structural database","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Crystallogr. Sect. B: Struct. Sci., Crystal Eng. Mater."},{"key":"10.1016\/j.ejpb.2019.06.029_b0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.addr.2003.10.008","article-title":"Drug polymorphism and dosage form design: a practical perspective","volume":"56","author":"Singhal","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.06.029_b0100","unstructured":"S.R. Byrn Jr. RRP, J.G. Stowell. 1999. Solid-state chemistry of drugs, 2 ed. SSCI, West Lafayette, IN."},{"key":"10.1016\/j.ejpb.2019.06.029_b0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jps.22788","article-title":"Polymorphism and solvatomorphism 2010","volume":"101","author":"Brittain","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.06.029_b0110","doi-asserted-by":"crossref","DOI":"10.15226\/2374-6866\/1\/2\/00111","article-title":"Polymorphism: the phenomenon affecting the performance of drugs","author":"Raza","year":"2014","journal-title":"SOJ Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.06.029_b0115","doi-asserted-by":"crossref","DOI":"10.3791\/3191-v","article-title":"Cercarial transformation and in vitro cultivation of Schistosoma mansoni schistosomules","author":"Milligan","year":"2011","journal-title":"J. Visual. Exp.: JoVE"},{"key":"10.1016\/j.ejpb.2019.06.029_b0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41596-018-0101-y","article-title":"Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni","volume":"14","author":"Lombardo","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2019.06.029_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000478","article-title":"Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening","volume":"3","author":"Abdulla","year":"2009","journal-title":"PLoS Negl.Trop. Dis."},{"key":"10.1016\/j.ejpb.2019.06.029_b0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s13071-016-1616-0","article-title":"Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections","volume":"9","author":"Keiser","year":"2016","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejpb.2019.06.029_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003962","article-title":"Activity profile of an FDA-approved compound library against Schistosoma mansoni","volume":"9","author":"Panic","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejpb.2019.06.029_b0140","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1128\/JCM.02382-10","article-title":"Isothermal microcalorimetry to study drugs against Schistosoma mansoni","volume":"49","author":"Manneck","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S0031182009990965","article-title":"Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni","volume":"137","author":"Manneck","year":"2010","journal-title":"Parasitology"},{"key":"10.1016\/j.ejpb.2019.06.029_b0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2019.06.029_b0155","unstructured":"FDA. 2018. Bioanalytical Method Validation Guidance for Industry. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.Pdf."},{"key":"10.1016\/j.ejpb.2019.06.029_b0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpba.2015.10.011","article-title":"Development and validation of an enantioselective LC\u2013MS\/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots","volume":"118","author":"Meister","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2019.06.029_b0165","unstructured":"R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.ejpb.2019.06.029_b0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijpara.2016.03.006","article-title":"Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population","volume":"46","author":"Chevalier","year":"2016","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0175","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.04875-14","article-title":"Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection","volume":"59","author":"El-Feky","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.06.029_b0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13318-012-0089-6","article-title":"Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice","volume":"37","author":"El-Lakkany","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2019.06.029_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005942","article-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model","volume":"11","author":"Abla","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejpb.2019.06.029_b0190","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijpara.2004.04.005","article-title":"Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination","volume":"34","author":"William","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0195","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/AAC.02741-14","article-title":"Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni","volume":"58","author":"Meister","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.06.029_b0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S0031182009991739","article-title":"In vitro and in vivo trematode models for chemotherapeutic studies","volume":"137","author":"Keiser","year":"2010","journal-title":"Parasitology"},{"key":"10.1016\/j.ejpb.2019.06.029_b0205","first-page":"614","article-title":"Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.ejpb.2019.06.029_b0210","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jpba.2018.01.030","article-title":"Evaluation of a novel micro-sampling device, Mitra\u2122, in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural C\u00f4te d'Ivoire","volume":"151","author":"Kova\u010d","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2019.06.029_b0215","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4103\/0250-474X.57283","article-title":"Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients","volume":"71","author":"Yadav","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.06.029_b0225","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/jps.23025","article-title":"Solution-mediated phase transformation: significance during dissolution and implications for bioavailability","volume":"101","author":"Greco","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.06.029_b0230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/dkt491","article-title":"The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer)","volume":"69","author":"Olliaro","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2019.06.029_b0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejpb.2019.06.029_b0240","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1645\/GE-865R.1","article-title":"Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities","volume":"92","author":"Botros","year":"2006","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ejpb.2019.06.029_b0245","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0035-9203(90)90333-A","article-title":"Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis","volume":"84","author":"Mandour","year":"1990","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejpb.2019.06.029_b0250","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/infdis\/157.3.530","article-title":"Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease","volume":"157","author":"Watt","year":"1988","journal-title":"J. Infect. Dis."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119302206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119302206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:37:11Z","timestamp":1760546231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119302206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":50,"alternative-id":["S0939641119302206"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.029","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}